Have a personal or library account? Click to login

Atomoxetine in the Treatment of the Most Common Comorbid Disorders of Attention-Deficit/Hyperactivity Disorder, Oppositional Defiant Disorder and Anxiety Disorders

Acta Medica Martiniana
Volume 12 (2012): Issue 3 (December 2012)
By:
Open Access
|Dec 2012

References

  1. 1. Faraone SV, Sergeant J, Gillberg C, Biederman J. The worldwide prevalence of ADHD: is it an American condition? World Psychiatry. 2003; 2:104-113
    Search in Google Scholar
  2. 2. Hechtman L. Assessment and diagnosis of attention-deficit/ hyperactivity disorder. Child Adolesc Psychiatr Clin N Am. 2000; 9:481-49810.1016/S1056-4993(18)30102-0
    Search in Google Scholar
  3. 3. Dell’Agnello G, Maschietto D, Pancotto A, Calamoneri F, Masi G, Curatolo P, Besana D, Mancini F, Rossi A, Escobar R, Zuddas A. Atomoxetine hydrochloride in the treatment of children and adolescents with attentiondeficit/ hyperactivity disorder and comorbid oppositional defiant disorder: Results from a placebo-controlled Italian study. Eur Neuropsychopharmacol. 2009; 19: 822-83410.1016/j.euroneuro.2009.07.008
    Search in Google Scholar
  4. 4. Pactl et al. Hyperkinetická porucha a poruchy chování. 1st ed. Praha: Grada Publishing.2007; 240s.
    Search in Google Scholar
  5. 5. Aosaki T, Graybiel AM, Kimura M. Effect of the nigrostriatal dopamine system on acquired neural responses in the striatum of behaving monkeys.Science. 1994; 265:412-41510.1126/science.8023166
    Search in Google Scholar
  6. 6. Goldman-Rakic PS. Working memory dysfunction in schizophrenia.J Neuropsychiatry Clin Neurosci. 1994;6:348-35710.1176/jnp.6.4.348
    Search in Google Scholar
  7. 7. Sawaguchi T, Matsumura M, Kubota K: Catecholaminergic effects on neuronal activity related to a delayed response task in monkey prefrontal cortex.J Neurophysiol.1990; 63:1385-140010.1152/jn.1990.63.6.1385
    Search in Google Scholar
  8. 8. Aston-Jones G, Bloom FE: Norepinephrine containing locus coeruleus neurons in behaving rats exhibit pronounced responses to non-noxious environmental stimuli.J Neuroscience.1981;1:887-90010.1523/JNEUROSCI.01-08-00887.1981
    Search in Google Scholar
  9. 9. MTA Cooperative Group.Arch Gen Psychiatry. 1999; 56: 1073-86
    Search in Google Scholar
  10. 10. Conley R, Gupta SK, Sathya G. Clinical spectrum of the osmotic-controlled release oral delivery system (OROS), an advanced oral delivery form.Curr Med Res Opin. 2006; 22(10):1879-9210.1185/030079906X132613
    Search in Google Scholar
  11. 11. Volkow N. et al. Association of methylphenidate-induced craving with changes in right striato-orbitofrontal metabolism in cocaine abusers: implications in addiction. Am J Psychiatry. 1999; 156 (1):19-2610.1176/ajp.156.1.19
    Search in Google Scholar
  12. 12. Solanto MV. Neuropsychopharmacological mechanisms of stimulant drug action in attention-deficit hyperactivity disorder: a review and integration. Behav Brain Res. 1998; 94: 127-5210.1016/S0166-4328(97)00175-7
    Search in Google Scholar
  13. 13. Wigal S B. Efficacy and Safety Limitations of Attention-Deficit Hyperactivity Disorder Pharmacotherapy in Children and Adults, CNS Drugs. 2009; 23 (1): 21
    Search in Google Scholar
  14. 14. Greydanus DE, Pratt HD, Patel DR. Attention deficit hyperactivity disorderacross the lifespan: the child, adolescent, and adult. Dis Mon .2007; 53 (2): 70-13.10.1016/j.disamonth.2007.01.00117386306
    Search in Google Scholar
  15. 15. Barton J. Atomoxetine: a new pharmacotherapeutic approach in the management of attention deficit/hyperactivity disorder. Arch Dis Child. 2005; 90:26-9.10.1136/adc.2004.059386
    Search in Google Scholar
  16. 16. Bymaster FP, Katner JS, Nelson DL, et al. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology.2002; 27(5): 699-71.110.1016/S0893-133X(02)00346-9
    Search in Google Scholar
  17. 17. Gehlert DR, Schober DA, Gackenheimer SL. Comparison of (R)-[‘H]tomoxetine and (R/S)-[‘H]nisoxetine binding in rat brain. J Neurochem. 1995; 64 (6): 2792-800.10.1046/j.1471-4159.1995.64062792.x7760060
    Search in Google Scholar
  18. 18. Wernicke JF, Faries D, Girod D, et al. Cardiovascular effects of atomoxetine in children, adolescents, and adults. Drug Saf. 2003; 26(10): 729-40.10.2165/00002018-200326100-0000612862507
    Search in Google Scholar
  19. 19. Spencer TJ, Kratochvil CJ, Sangal RB, et al. Effects of atomoxetine on growth in children with attentiondeficit/ hyperactivity disorder following up to five years of treatment. J Child Adolesc Psychopharmacol. 2007; 17(5): 689-700.10.1089/cap.2006.010017979588
    Search in Google Scholar
  20. 20. Sangal RB, Owens J, Allen AJ, et al. Effects of atomoxetine and methylphenidat on sleep in children with ADHD. Sleep. 2006; 29(12): 1573-85.10.1093/sleep/29.12.157317252888
    Search in Google Scholar
  21. 21. Witcher JW, Long A, Smith B, et al. Atomoxetine pharmacokinetics in children and adolescents with attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol. 2003; 13: 53-63.10.1089/10445460332166619912804126
    Search in Google Scholar
  22. 22. Eli Lilly and Company. Atomoxetine (Strattera™) prescribing information [online]. Available from URL: http://pi.lilly.com/tis/strattera-pi.pdf [Accessed 2009 Feb 9].
    Search in Google Scholar
  23. 23. Sauer J.M., Ring B.J., Witcher J.W. Clinical pharmacokinetics of atomoxetine. Clin Pharmacokinet. 2005; 44:571-590.10.2165/00003088-200544060-0000215910008
    Search in Google Scholar
  24. 24. Michelson D. et al. Addition of atomoxetine for depression incompletely responsive to sertraline: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2007; 68:582-587.10.4088/JCP.v68n0414
    Search in Google Scholar
  25. 25. Michelson D, Allen AJ, Busner J, Casat C, Dunn D, Kratochvil C, Newcorn J, Sallee RF, Sangal RB, Saylor K, West S, Kelsey D, Wernicke J, Trapp NJ, Harder D.Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: A randomized, placebo-controlled study. Am J Psychiatry.2002;159:1896-190110.1176/appi.ajp.159.11.189612411225
    Search in Google Scholar
  26. 26. Jensen PS, Hinshaw SP, Kraemer HC, Lenora N, Newcorn JH, Abikoff HB, March JS, Arnold LE, Cantwell DP, Conners CK, Elliott GR, Greenhill LL, Hechtman L, Hoza B, Pelham WE, Severe JB, Swanson JM, Wells KC, Wigal T, Vitiello B. ADHD comorbidity findings from the MTA study: comparing comorbid subgroups. J Am Acad Child Adolesc Psychiatry. 2001; 40:147-15810.1097/00004583-200102000-0000911211363
    Search in Google Scholar
  27. 27. Kuhne M, Schachar R, Tannock R. Impact of comorbid oppositional or conduct problems on attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 1197; 36:1715-172510.1097/00004583-199712000-000209401333
    Search in Google Scholar
  28. 28. Raine A, Venables PH, Williams M. Relationships between central and autonomic measures of arousal at age 15 years and criminality at age 24 years. Arch Gen Psychiatry. 1990;47:1003-7.10.1001/archpsyc.1990.018102300190032241502
    Search in Google Scholar
  29. 29. AACAP Official Action.. Practice parameters for the assessment and treatment of children and adolescents with conduct disorder. J Am Acad Child Adolesc Psychiatry. 1997:36:122-39.
    Search in Google Scholar
  30. 30. Lahey BB, Hart EL, Pliszka S, Applegate B, McBurnett K. Neurophysiological correlates of conduct disorder: a rationale and a review. J Clin Child Psychol. 1993;22:141-53.10.1207/s15374424jccp2202_2
    Search in Google Scholar
  31. 31. Masi G, Manfredi A, Milone A. Predictors of nonresponse to psychosocial treatment in children and adolescents with disruptive behavior disorders. J Child Adolesc Psychopharmacol. 2011; 21:51-55.10.1089/cap.2010.003921309697
    Search in Google Scholar
  32. 32. American Academy of Child & Adolescent Psychiatry (AACAP). Preventive effects of treatment of disruptive behavior disorder in middle childhood on substance use and delinquent behavior. Journal of the American Academy of Child and Adolescent Psychiatry. 2007; 46 (1): 33-39.10.1097/01.chi.0000246051.53297.5717195727
    Search in Google Scholar
  33. 33. Sondeijker FEPL, Ferdinand RF, Oldehinkel AJ, Veenstra R, De Winter AF, Ormel J, Verhulst FC. Classes of adolescentswith disruptive behaviors in a general population sample. Soc Psychiatry Psychiatr Epidemiol. 2005; 40:931-93810.1007/s00127-005-0970-616222441
    Search in Google Scholar
  34. 34. Burns GL, Walsh JA. The influence of ADHD-hyperactivity/ impulsivity symptoms on the development of oppositional defiant disorder symptoms in a 2-year longitudinal study. J Abnorm Child Psychol. 2002; 30:245-25610.1023/A:1015102812958
    Search in Google Scholar
  35. 35. Chen TJH, Blum K, Mathews D, Fisher L, Schnautz N, Braverman ER, Schoolfield J, Downs BW, Comings DE. Are dopaminergic genes involved in a predisposition to pathological aggression? Hypothesizing the importance of “super normal controls” in psychiatricgenetic research of complex behavioral disorders. Med Hypotheses. 2005;65:703-70710.1016/j.mehy.2005.04.03715964153
    Search in Google Scholar
  36. 36. Comings DE, Chen C, Wu S, Muhleman D. Association of the androgen receptor gene (AR) with ADHD and conduct disorder. Neuroreport. 1999; 10:1589-159210.1097/00001756-199905140-0003610380986
    Search in Google Scholar
  37. 37. Oosterlaan J, Scheres A, Sergeant JA.Which executive functioning deficits are associated with AD/HD, ODD/CD and comorbid AD/HD+ODD/CD? J Abnorm Child Psychol.2005; 33:69-8510.1007/s10802-005-0935-y15759592
    Search in Google Scholar
  38. 38. Baving L, Rellum T, Kaucht M, Schmidt MH.Children with oppositional-defiant disorder display deviant attentional processingindependent of ADHD symptoms. J Neural Transm.2006;113:685-6910.1007/s00702-005-0345-x16082512
    Search in Google Scholar
  39. 39. Swanson JM, Kraemer HC, Hinshaw SP, Arnold LE, Conners CK, Abikoff HB, Clevenger W, Davies M, Elliott GR, Greenhill LL, Hechtman L, Hoza B, Jensen PS, March JS, Newcorn JH, Owens EB, Pelham WE, Schiller E, Severe JB, Simpson S, Vitiello B, Wells K, Wigal T, Wu M: Clinical relevance of the primary findings of the MTA: Success rates based on severity of ADHD and ODD symptoms at the end of treatment. J Am Acad Child Adolesc Psychiatry.2001;40:168-17910.1097/00004583-200102000-0001111211365
    Search in Google Scholar
  40. 40. Bangs ME, Hazell P, Danckaerts M, Hoare P, Coghill DR, Wehmeier PM, Williams DW, Moore RJ, Levine L; Atomoxetine ADHD/ODD Study Group: Atomoxetine for the treatment of attentiondeficit/ hyperactivity disorder and oppositional defiant disorder. Pediatrics.2008; 121:314-2010.1542/peds.2006-188018245404
    Search in Google Scholar
  41. 41. Kelsey DK, Sumner CR, Casat CD, Coury DL, Quintana H, Saylor KE, Sutton VK, Gonzales J, Malcolm SK, Schuh KJ, Allen AJ. Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebocontrolled trial. Pediatrics.2004; 114(1):1-810.1542/peds.114.1.e115231966
    Search in Google Scholar
  42. 42. Kaplan S, Heiligenstein J, West S, Busner J, Harder D, Dittmann R, Casat C, Wernicke JF. Efficacy and safety of atomoxetine in childhood attention-deficit/hyperactivity disorder with comorbid oppositional defiant disorder. J Atten Disord. 2004; 8:45-5210.1177/10870547040080020215801334
    Search in Google Scholar
  43. 43. Newcorn J, Spencer TJ, Biederman J, Milton DR, Michelson D. Atomoxetine treatment in children and adolescents with attentiondeficit/ hyperactivity disorder and comorbid oppositional defiant disorder. J Am Acad Child Adolesc Psychiatry.2005; 44:240-24810.1097/00004583-200503000-0000815725968
    Search in Google Scholar
  44. 44. Biederman J, Spencer TJ, Newcorn JH, Gao H, Milton DR, Feldman PD, Witte MM: Effect of comorbid symptoms of oppositional defiant disorder on responses to atomoxetine in children with ADHD: A meta-analysis of controlled clinical trial data. Psychopharmacology.2007; 190:31-4110.1007/s00213-006-0565-217093981
    Search in Google Scholar
  45. 45. Anderson et al. Arch Gen Psychiatry.1987; 44(1):69 -7610.1001/archpsyc.1987.018001300810102432848
    Search in Google Scholar
  46. 46. Jennifer SB, Mark RD . Examining Alternative Explanations of the Covariation of ADHD and Anxiety Symptoms in Children. A Community Study J Abnorm Child Psychol. 2008; 36:67-7910.1007/s10802-007-9160-117636434
    Search in Google Scholar
  47. 47. Pliszka SR. Effect of anxiety on cognition, behavior, and stimulant response in ADHD. Journal of American Academy of Child & Adolescent Psychiatry.1989; 28:882-88710.1097/00004583-198911000-000122808258
    Search in Google Scholar
  48. 48. Costin J, Vance A, Barnett R, O’Shea M, Luk E. Attention deficit hyperactivity disorder and comorbid anxiety: Practitioner problems in treatment planning. Child & Adolescent Mental Health, 2002; 7:16-2410.1111/1475-3588.00005
    Search in Google Scholar
  49. 49. Taylor E, Schachar R, Thorley G, Wieselberg HM, Everitt B, Rutter M. Which boys respond to stimulant medication? A controlled trial of MPH in boys with disruptive behavior. Psychol Med.1987;17:121-14310.1017/S0033291700013039
    Search in Google Scholar
  50. 50. Diamond IR, Tannock R, Achachar RJ. Response to methylphenidate in children with ADHD and comorbid anxiety. J Am Acad Child Adolesc Psychiatry. 1999; 38:402-40910.1097/00004583-199904000-0001210199111
    Search in Google Scholar
  51. 51. Kratochvil, Newcorn, Arnold L, Duesenberg, Emslie, Quintana, Sarkis, Wagner, GaoAO, Michelson, Biederman. Atomoxetine alone or combined with fluoxetine for treating ADHD with comorbid depressive or anxiety aymptoms. J. Am. Acad. Child Adolesc. Psychiatry. 2005; 44(9): 915-24
    Search in Google Scholar
  52. 52. Cheng JY, Chen RY, Ko JS, Ng EM. Efficacy and safety of atomoxetine for attention-deficit/hyperactivity disorder in children and adolescents-meta-analysis and meta-regression analysis. Psychopharmacology. 2007; 194:197-20910.1007/s00213-007-0840-x17572882
    Search in Google Scholar
  53. 52. Geller, Donnelly, Lopez, Rubin, Newcorn, Sutton, Bakken, Packowski, Kelsey, Sumner. Atomoxetine treatment for pediatric patients with attention-deficit/hyperactivity disorder with comorbid anxiety disorder. J. Am. Acad. Child Adolesc Psychiatry. 2007;46(9): 111910.1097/chi.0b013e3180ca838517712235
    Search in Google Scholar
  54. 53. Milberger S, Biederman J, Faraone SV, Murphy J, Tsuang MT. Attention deficit hyperactivity disorder and comorbid disorders: Issues of overlapping symptoms. American Journal of Psychiatry.1995; 152: 1793-179910.1176/ajp.152.12.17938526248
    Search in Google Scholar
DOI: https://doi.org/10.2478/v10201-011-0039-z | Journal eISSN: 1338-4139 | Journal ISSN: 1335-8421
Journal RSS Feed
Language: English
Page range: 28 - 38
Published on: Dec 28, 2012
Published by: Sciendo
In partnership with: Paradigm Publishing Services
Publication frequency: 3 times per year
Keywords:
ADHD,
comorbidity,
ODD,
anxiety,
atomoxetine
Related subjects:
Medicine,
Clinical medicine,
Internal medicine,
Cardiology

© 2012 E. Snircova, T. Kulhan, G. Nosalova, I. Ondrejka, published by Sciendo
This work is licensed under the Creative Commons License.

Previous articleVolume 12 (2012): Issue 3 (December 2012)Next article